Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

• Status: Terminated
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance.

PURPOSE: This laboratory study is looking at tamoxifen resistance in women with stage I, stage II, stage IIIA, or stage IIIB breast cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Comprehensive Cancer Center of Wake Forest University; Wake Forest University Health Sciences
• Collaborator: National Cancer Institute (NCI)
• Treatments: Tamoxifen

Criteria

Inclusion Criteria:

• Histologically confirmed invasive breast cancer

• Initial pathologic stage I-IIIB disease

• No stage IV disease

• Meets the following criteria for breast cancer therapy:

• Received prior primary local therapy for breast cancer

• Scheduled to begin tamoxifen citrate as adjuvant therapy for breast cancer within 3 weeks

• Hormone receptor status:

• Estrogen-receptor positive tumor

• Female

• Pre- or post-menopausal

• Must be able to donate 20 mL of blood

Exclusion Criteria:

• Severe anemia, defined as hemoglobin < 11 g/dL

• Psychiatric history that would preclude obtaining informed consent